TABLE 3.

Serum anti-PRP IgG subclass concentrations at postprimary and booster time pointsa

StudyGroupNo. of subjects testedGMC (μg/ml) (95% CI)IgG1/IgG2 ratio
IgG1IgG2
United States
    PostprimaryDTPa + HBV + OPV + Hib*211.83 (0.62-5.36)1.01 (0.59-1.72)1.81
DTPa-HBV-IPV/Hib171.15 (0.56-2.37)0.27 (0.17-0.44)4.17
    PostboosterDTPa + Hib*3317.77 (8.77-36.01)3.615 (2.33-5.6)4.91
DTPa/Hib3115.48 (7.9-30.29)5.09 (3.25-7.95)3.18
Germany B
    PostprimaryDTPa-HBV/Hib250.547 (0.31-0.97)0.213 (0.17-0.27)3.5
DTPa-HBV + Hib215.204 (2.16-12.53)0.614 (0.36-1.04)8.5
    PreboosterDTPa-HBV/Hib250.253 (0.17-0.37)0.155 (0.14-0.17)3.0
DTPa-HBV + Hib250.679 (0.3-1.51)0.182 (0.14-0.24)7.2
    Postboosterdtpa-HBV-PRP256.175 (2.34-16.3)1.967 (0.98-3.95)3.7
dtpa-HBV + PRP2121.254 (6.27-72.04)4.774 (2.01-11.35)4.5
  • a Not evaluated in Germany A and Myanmar studies. Blood samples were collected 1 month after the three-dose primary series and 4 to 6 weeks after the booster dose. CI, confidence interval; dtpa, experimental DTPa vaccine with reduced antigen content; OPV, oral poliovirus vaccine. *, OmniHIB.